Treatment involves therapeutic plasma exchange (TPE) together with immune suppression in autoimmune (acquired) TTP or replacement of deficient ADAMTS13 with fresh frozen plasma (FFP) infusions in the case of USS [2]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.